Fig. 2From: Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United StatesTreatment patterns after aromatase inhibitors in first line (n = 103) – from chart review. Data show absolute frequencies of treatments received in second line for patients that received anastrozole (n = 63), letrozole (n = 34) or exemestane (n = 6) in first lineBack to article page